​

Funding Round

Post-IPO Equity - Unicycive Therapeutics

Post-IPO Equity - Unicycive Therapeutics

Investment Firm

Overview

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.

Announced Date

Mar 06, 2023

Funding Type

Post Ipo Equity

Highlights

Location

United States, North America

Social

Investor Lead

Vivo Capital

Vivo Capital

Vivo Capital is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

Participant Investors

5

Investor Name
Participant InvestorNantahala Capital Management
Participant InvestorLogos Capital
Participant InvestorBiotechnology Value Fund
Participant InvestorRA Capital Management
Participant InvestorVivo Capital

Round Details and Background

Unicycive Therapeutics raised $30000000 on 2023-03-06 in Post-IPO Equity

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 12, 2019
Series A - Unicycive Therapeutics
-6.0M
Mar 06, 2023
Post-IPO Equity - Unicycive Therapeutics
5-30.0M
Jun 03, 2020
Seed Round - Unicycive Therapeutics
-604.1K
Mar 14, 2024
Post-IPO Equity - Unicycive Therapeutics
8-50.0M

Recent Activity

There is no recent news or activity for this profile.